These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24633366)

  • 1. Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial.
    Chen YJ; Meng FY; Mao Q; Li JX; Wang H; Liang ZL; Zhang YT; Gao F; Chen QH; Hu Y; Ge ZJ; Yao X; Guo HJ; Zhu FC; Li XL
    Hum Vaccin Immunother; 2014; 10(5):1366-72. PubMed ID: 24633366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months.
    Hu YM; Wang X; Wang JZ; Wang L; Zhang YJ; Chang L; Liang ZL; Xia JL; Dai QG; Hu YL; Mao QY; Zhu FC; Song YF; Gao F; Chen JT
    Clin Vaccine Immunol; 2013 Dec; 20(12):1805-11. PubMed ID: 24108780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation.
    Hu Y; Zeng G; Chu K; Zhang J; Han W; Zhang Y; Li J; Zhu F
    Hum Vaccin Immunother; 2018 Jun; 14(6):1517-1523. PubMed ID: 29482422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A booster dose of an inactivated enterovirus 71 vaccine in chinese young children: a randomized, double-blind, placebo-controlled clinical trial.
    Shenyu W; Jingxin L; Zhenglun L; Xiuling L; Qunying M; Fanyue M; Hua W; Yuntao Z; Fan G; Qinghua C; Yuemei H; Xin Y; Huijie G; Fengcai Z
    J Infect Dis; 2014 Oct; 210(7):1073-82. PubMed ID: 24625805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints.
    Zhu W; Jin P; Li JX; Zhu FC; Liu P
    Expert Rev Vaccines; 2017 Sep; 16(9):945-949. PubMed ID: 28548626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals.
    Mao Q; Wang Y; Shao J; Ying Z; Gao F; Yao X; Li C; Ye Q; Xu M; Li R; Zhu F; Liang Z
    Hum Vaccin Immunother; 2015; 11(11):2723-33. PubMed ID: 25715318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial.
    Zhu FC; Liang ZL; Li XL; Ge HM; Meng FY; Mao QY; Zhang YT; Hu YM; Zhang ZY; Li JX; Gao F; Chen QH; Zhu QY; Chu K; Wu X; Yao X; Guo HJ; Chen XQ; Liu P; Dong YY; Li FX; Shen XL; Wang JZ
    Lancet; 2013 Mar; 381(9871):1037-45. PubMed ID: 23352749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative analysis of immunogenicity and safety of an enterovirus 71 vaccine between children aged 3-5 years and infants aged 6-35 months.
    Gu W; Zeng G; Hu YM; Hu YS; Zhang Y; Hu YL; Wang Y; Li JX; Zhu FC
    Expert Rev Vaccines; 2018 Mar; 17(3):257-262. PubMed ID: 29363365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6-35 months.
    Jin P; Li J; Zhang X; Meng F; Zhou Y; Yao X; Gan Z; Zhu F
    Hum Vaccin Immunother; 2016 Apr; 12(4):916-21. PubMed ID: 26751765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interchangeability of two Enterovirus 71 inactivated vaccines in Chinese children: A phase IV, open-label, and randomized controlled trial.
    Xu Q; Cao Q; Yang W; Liu X; Liu H; Tian X; Li J; Fang X; Jia N; Zeng G; Xu A
    Vaccine; 2020 Mar; 38(12):2671-2677. PubMed ID: 32067817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial.
    Li YP; Liang ZL; Gao Q; Huang LR; Mao QY; Wen SQ; Liu Y; Yin WD; Li RC; Wang JZ
    Vaccine; 2012 May; 30(22):3295-303. PubMed ID: 22426327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An inactivated enterovirus 71 vaccine is safe and immunogenic in healthy adults: A phase I, double blind, randomized, placebo-controlled, study of two dosages.
    Tambyah PA; Oon J; Asli R; Kristanto W; Hwa SH; Vang F; Karwal L; Fuchs J; Santangelo JD; Gordon GS; Thomson C; Rao R; Dean H; Das SC; Stinchcomb DT
    Vaccine; 2019 Jul; 37(31):4344-4353. PubMed ID: 31230881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study.
    Wei M; Meng F; Wang S; Li J; Zhang Y; Mao Q; Hu Y; Liu P; Shi N; Tao H; Chu K; Wang Y; Liang Z; Li X; Zhu F
    J Infect Dis; 2017 Jan; 215(1):56-63. PubMed ID: 28077584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, Randomized, double-blind, placebo-controlled Trial.
    Li YP; Liang ZL; Xia JL; Wu JY; Wang L; Song LF; Mao QY; Wen SQ; Huang RG; Hu YS; Yao X; Miao X; Wu X; Li RC; Wang JZ; Yin WD
    J Infect Dis; 2014 Jan; 209(1):46-55. PubMed ID: 23922377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of the lot-to-lot consistency of an enterovirus 71 vaccine in a commercial-scale phase IV clinical trial.
    Chen J; Jin P; Chen X; Mao Q; Meng F; Li X; Chen W; Du M; Gao F; Liu P; Li X; Guo C; Xie T; Lu W; Li Q; Li L; Yan X; Guo X; Du H; Li X; Duan K; Zhu F
    Hum Vaccin Immunother; 2022 Nov; 18(5):2063630. PubMed ID: 35714273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu FC; Meng FY; Li JX; Li XL; Mao QY; Tao H; Zhang YT; Yao X; Chu K; Chen QH; Hu YM; Wu X; Liu P; Zhu LY; Gao F; Jin H; Chen YJ; Dong YY; Liang YC; Shi NM; Ge HM; Liu L; Chen SG; Ai X; Zhang ZY; Ji YG; Luo FJ; Chen XQ; Zhang Y; Zhu LW; Liang ZL; Shen XL
    Lancet; 2013 Jun; 381(9882):2024-32. PubMed ID: 23726161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: a report of further observations.
    Liu L; Mo Z; Liang Z; Zhang Y; Li R; Ong KC; Wong KT; Yang E; Che Y; Wang J; Dong C; Feng M; Pu J; Wang L; Liao Y; Jiang L; Tan SH; David P; Huang T; Zhou Z; Wang X; Xia J; Guo L; Wang L; Xie Z; Cui W; Mao Q; Liang Y; Zhao H; Na R; Cui P; Shi H; Wang J; Li Q
    BMC Med; 2015 Sep; 13():226. PubMed ID: 26381232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive safety assessment of a human inactivated diploid enterovirus 71 vaccine based on a phase III clinical trial.
    Zhang W; Kong Y; Jiang Z; Li C; Wang L; Xia J
    Hum Vaccin Immunother; 2016 Apr; 12(4):922-30. PubMed ID: 26837471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan.
    Huang LM; Chiu CH; Chiu NC; Lin CY; Li MT; Kuo TY; Weng YJ; Hsieh EF; Tai IC
    Vaccine; 2019 Mar; 37(13):1827-1835. PubMed ID: 30803843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced neutralizing antibody response induced by inactivated enterovirus 71 in cynomolgus monkeys.
    In HJ; Lim H; Lee JA; Lee SR; Jin YB; Jeong KJ; Hyeon JY; Yoo JS; Lee JW; Choi YK; Lee SW
    PLoS One; 2018; 13(10):e0202552. PubMed ID: 30278051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.